Quotient Clinical (“Quotient”), the drug development services provider, today announced the appointment of Azhar Kalim as Chief Commercial Officer (CCO). Azhar will lead the enhanced commercial team in a new role, with a focus on supporting Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions.
Quotient’s integrated capabilities incorporate formulation development, GMP drug product manufacturing and early stage clinical trials. The acquisitions of SeaView Research, a specialist early phase clinical pharmacology business, and QS Pharma, a small molecule formulation development and manufacturing business, were announced in February.
Azhar will be responsible for global commercial activities to support Quotient’s integrated services. He will be instrumental in directing the global commercial team in terms of strategic marketing, business development, innovation, key account management, and customer service to biotech and pharmaceutical clients across the globe.
Mark Egerton, Chief Executive Officer, Quotient, said: “Azhar has over 25 years’ experience in the drug development services sector, as a leader in expanding research capabilities and creating unique service offerings to the biopharma industry. Quotient takes pride in being a highly customer focused organisation and we are delighted to welcome Azhar in this vital role at an exciting point in the company’s development. I look forward to working with him on a continued journey of growth and success.”
Azhar Kalim commented: “Quotient’s integrated capabilities offer a unique solution to our clients. I am delighted to be joining a dynamic and rapidly expanding business, and I look forward to working with the team to build long term, sustainable, and strategic relationships with our customers.”
To find out more about Quotient Clinical, please go to the website.
